Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Lancet. Infectious Diseases (Print)

• Publication date

  2011-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S1473-3099(11)70098-6PMID 21570355PMCID PMC3417349
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Host genetic determinants of T cell responses to the MRKAd5 HIV-1 gag/pol/nef vaccine in the step trial.

  2011cited by this paper
• International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials.

  2010cited by this paper
• Response definition criteria for ELISPOT assays revisited

  2010cited by this paper
• Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine

  2010cited by this paper
• HIV molecular epidemiology: transmission and adaptation to human populations

  2009cited by this paper
• Uptake of male circumcision in an HIV vaccine efficacy trial.

  2009cited by this paper
• South African national HIV prevalence, incidence, behaviour and communication survey, 2008: a turning tide among teenagers?

  2009cited by this paper
• Functional properties and epitope characteristics of T-cells recognizing natural HIV-1 variants.

  2009cited by this paper
• HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis.

  2008cited by this paper
• Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.

  2008cited by this paper
• Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults.

  2008cited by this paper
• HIV Type 1 Subtype C gag and nef Diversity in Southern Africa

  2007cited by this paper
• Synergistic copathogens--HIV-1 and HSV-2.

  2007cited by this paper
• Hormonal contraception and the risk of HIV acquisition

  2007cited by this paper
• Detection of HIV Vaccine-Induced Cell-Mediated Immunity in HIV-Seronegative Clinical Trial Participants Using an Optimized and Validated Enzyme-Linked Immunospot Assay

  2007cited by this paper
• Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies

  2006cited by this paper
• AIDS Res Hum Retroviruses

  2006cited by this paper
• A Comparison of Standard Immunogenicity Assays for Monitoring HIV Type 1 gag-Specific T Cell Responses in Ad5 HIV Type 1 gag Vaccinated Human Subjects

  2006cited by this paper
• The Impact of Incident and Prevalent Herpes Simplex Virus-2 Infection on the Incidence of HIV-1 Infection Among Commercial Sex Workers in South Africa

  2005cited by this paper
• Cross-reactivity of anti-HIV-1 T cell immune responses among the major HIV-1 clades in HIV-1-positive individuals from 4 continents.

  2005cited by this paper
• Quantitative Adenovirus Neutralization Assays Based on the Secreted Alkaline Phosphatase Reporter Gene: Application in Epidemiologic Studies and in the Design of Adenovector Vaccines

  2004cited by this paper
• Highly Effective Control of an AIDS Virus Challenge in Macaques by Using Vesicular Stomatitis Virus and Modified Vaccinia Virus Ankara Vaccine Vectors in a Single-Boost Protocol

  2004cited by this paper
• Prevalence of Neutralizing Antibodies to Adenoviral Serotypes 5 and 35 in the Adult Populations of The Gambia, South Africa, and the United States

  2004cited by this paper
• The Effects of Herpes Simplex Virus-2 on HIV-1 Acquisition and Transmission: A Review of Two Overlapping Epidemics

  2004cited by this paper
• Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors.

  2004cited by this paper
• Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

  2002cited by this paper
• Simultaneous Inferences on the Contrast of Two Hazard Functions with Censored Observations

  2002cited by this paper
• The epidemiology of HSV-2 infection and its association with HIV infection in four urban African populations

  2001cited by this paper
• Association between Virus-Specific Cytotoxic T-Lymphocyte and Helper Responses in Human Immunodeficiency Virus Type 1 Infection

  1999cited by this paper
• Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia.

  1997cited by this paper
• Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers.

  1997cited by this paper
• Strong Cytotoxic T Cell and Weak Neutralizing Antibody Responses in a Subset of Persons with Stable Nonprogressing HIV Type 1 Infection

  1996cited by this paper
• Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics

  1995cited by this paper
• Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera

  1988cited by this paper
• Printed in Great Britain

  1970cited by this paper

• Adenovirus type 5 vector-based COVID-19 vaccine does not increase the likelihood of HIV infection.

  2026cites this paper
• Associations between the microbiome and immune responses to an adenovirus-based HIV-1 candidate vaccine are distinct between African and US cohorts

  2026cites this paper
• Sex Differences in Response to Viral Vector Vaccines—Implications for Future Vaccine Design

  2026cites this paper
• Understanding the performance of HIV-1 viral vector vaccines: adenovirus and poxvirus case studies

  2026cites this paper
• Decade-Long Sustained Cellular Immunity Induced by Sequential and Repeated Vaccination with Four Heterologous HIV Vaccines in Rhesus Macaques

  2025cites this paper
• HIV vaccine - Is there a ray of hope in the rugged journey?

  2025cites this paper
• Targeting HIV-1 immune escape mechanisms: Key advances and challenges in HIV-1 vaccine design.

  2025cites this paper
• Safety and broad immunogenicity of HIVconsvX conserved mosaic candidate T-cell vaccines vectored by ChAdOx1 and MVA in HIV-CORE 006: a double-blind, randomised, placebo-controlled phase 1 trial in healthy adults living without HIV-1 in eastern and southern Africa

  2025cites this paper
• mRNA vaccines against HIV: Hopes and challenges

  2025cites this paper
• Exploitation of Unconventional CD8 T-Cell Responses Induced by Engineered Cytomegaloviruses for the Development of an HIV-1 Vaccine

  2025cites this paper
• Safety, Effectiveness and Immunogenicity of heterologous mRNA-1273 Boost after Prime with Ad26.COV2.S among Healthcare Workers in South Africa: the single-arm, open-label, Phase 3 SHERPA Study

  2024cites this paper
• HIV-1 Gag, Pol, and Env diversified with limited adaptation since the 1980s

  2024cites this paper
• Mosaic HIV-1 vaccine and SHIV challenge strain V2 loop sequence identity and protection in primates

  2024cites this paper
• The Question of HIV Vaccine: Why Is a Solution Not Yet Available?

  2024cites this paper
• Insights from HIV-1 vaccine and passive immunization efficacy trials.

  2024cites this paper
• Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial

  2024cites this paper
• Exploring HIV Vaccine Progress in the Pre-Clinical and Clinical Setting: From History to Future Prospects

  2024cites this paper
• Meta-analysis of Pregnancy Events in Biomedical HIV Prevention Trials in Sub-Saharan Africa: Implications for Gender Transformative Trials

  2024cites this paper
• Nucleic Acid Vaccines Encoding Proteins and Virus-like Particles for HIV Prevention

  2024cites this paper
• Human Immunodeficiency Virus Vaccine: Promise and Challenges.

  2024cites this paper
• HIV Vaccine Development at a Crossroads: New B and T Cell Approaches

  2024cites this paper
• Pre–Human Immunodeficiency Virus (HIV) α4β7hi CD4+ T Cells and HIV Risk Among Heterosexual Individuals in Africa

  2024cites this paper
• Loss of HIV candidate vaccine efficacy in male macaques by mucosal nanoparticle immunization rescued by V2-specific response

  2024cites this paper
• Clinical trials and recent progress in HIV vaccine development

  2024cites this paper
• Vaccine Strategies to Elicit Mucosal Immunity

  2024cites this paper
• Safety, effectiveness and immunogenicity of heterologous mRNA-1273 boost after prime with Ad26.COV2.S among healthcare workers in South Africa: The single-arm, open-label, phase 3 SHERPA study

  2024cites this paper
• HIV-1 protective epitope-specific CD8+ T cells in HIV-1-exposed seronegative individuals

  2023cites this paper
• Generating and measuring effective vaccine-elicited HIV-specific CD8+ T cell responses

  2023cites this paper
• HIV and COVID-19 Disease

  2023cites this paper
• HIV epidemiology, prevention, treatment, and implementation strategies for public health.

  2023cites this paper
• Vaccine plus microbicide effective in preventing vaginal SIV transmission in macaques

  2023cites this paper
• Features of functional and dysfunctional CD8+ T cells to guide HIV vaccine development

  2023cites this paper
• Comparative Analysis of Primary and Monovalent Booster SARS-CoV-2 Vaccination Coverage in Adults with and without HIV in Catalonia, Spain

  2023cites this paper
• High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials

  2023cites this paper
• Cholera toxin B scaffolded, focused SIV V2 epitope elicits antibodies that influence the risk of SIVmac251 acquisition in macaques

  2023cites this paper
• Prophylactic HIV-1 vaccine trials: past, present, and future.

  2023cites this paper
• Sex and prior exposure jointly shape innate immune responses to a live herpesvirus vaccine

  2023cites this paper
• Analysis of the HVTN 702 Phase 2b-3 HIV-1 vaccine trial in South Africa assessing RV144 antibody and T-cell correlates of HIV-1 acquisition risk.

  2022cites this paper
• LAMP-1 Chimeric to HIV-1 p55Gag in the Immunization of Neonate Mice Induces an Early Germinal Center Formation and AID Expression

  2022cites this paper
• Randomised trials of COVID-19 vaccines in Africa – charting the path forward

  2022cites this paper
• The potential role of exosomal miRNAs and membrane proteins in acute HIV-infected people

  2022cites this paper
• COVID-19 vaccination and HIV-1 acquisition

  2022cites this paper
• Baseline host determinants of robust human HIV-1 vaccine-induced immune responses: A meta-analysis of 26 vaccine regimens

  2022cites this paper
• Aerosol delivery, but not intramuscular injection, of adenovirus-vectored tuberculosis vaccine induces respiratory-mucosal immunity in humans

  2022cites this paper
• Peptides for Vaccine Development

  2022cites this paper
• Fc receptors and the diversity of antibody responses to HIV infection and vaccination

  2022cites this paper
• Reappraising the Value of HIV-1 Vaccine Correlates of Protection Analyses

  2022cites this paper
• Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies

  2022cites this paper
• Adenovirus-based vaccines—a platform for pandemic preparedness against emerging viral pathogens

  2022cites this paper
• Assessment of a diverse panel of transmitted/founder HIV-1 infectious molecular clones in a luciferase based CD8 T-cell mediated viral inhibition assay

  2022cites this paper
• The Effect of Treatment-Associated Mutations on HIV Replication and Transmission Cycles

  2022cites this paper
• Adaptation to HLA-associated immune pressure over the course of HIV infection and in circulating HIV-1 strains

  2022cites this paper
• COVID-19 vaccines for high risk and immunocompromised patients

  2022cites this paper
• Seroprevalence of Binding and Neutralizing Antibodies against 39 Human Adenovirus Types in Patients with Neuromuscular Disorders

  2022cites this paper
• Optimal sequence-based design for multi-antigen HIV-1 vaccines using minimally distant antigens

  2022cites this paper
• Current Vaccine Platforms in Enhancing T-Cell Response

  2022cites this paper
• Analysis of the Prevalence of Binding and Neutralizing Antibodies against 39 Human Adenovirus Types in Student Cohorts Reveals Low-Prevalence Types and a Decline in Binding Antibody Levels during the SARS-CoV-2 Pandemic

  2022cites this paper
• Analysis of the Cytopathogenic Effect of Different HIV-1 Vpr Isoforms on Primary Human CD4+ T Cells and a Model Cell Line

  2022cites this paper
• For ty years on: how close is an HIV vaccine?

  2021cites this paper
• Adjuvant‐mediated enhancement of the immune response to HIV vaccines

  2021cites this paper
• Molecular insights into antibody-mediated protection against the prototypic simian immunodeficiency virus

  2021cites this paper
• FcγR Genetic Variation and HIV-1 Vaccine Efficacy: Context And Considerations

  2021cites this paper
• COVID-19 Vaccines for HIV-Infected Patients

  2021cites this paper
• Sterilizing Immunity against COVID-19: Developing Helper T cells I and II activating vaccines is imperative

  2021cites this paper
• Deep sequencing of the HIV-1 polymerase gene for characterisation of cytotoxic T-lymphocyte epitopes during early and chronic disease stages

  2021cites this paper
• Global and Regional Estimates for Subtype-Specific Therapeutic and Prophylactic HIV-1 Vaccines: A Modeling Study

  2021cites this paper
• An Update on the HIV DNA Vaccine Strategy

  2021cites this paper
• Preventive HIV Vaccines-Leveraging on Lessons from the Past to Pave the Way Forward

  2021influential citation
• Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk

  2021cites this paper
• A tale of four studies: HIV vaccine immunogenicity and efficacy in clinical trials.

  2021cites this paper
• Recombinant MVA-prime elicits neutralizing antibody responses by inducing antigen-specific B cells in the germinal center

  2021cites this paper
• Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial

  2021cites this paper
• Current approaches to HIV vaccine development: a narrative review

  2021influential citation
• Benign ethnic neutropenia in a South African population, and its association with HIV acquisition and adverse event reporting in an HIV vaccine clinical trial

  2021cites this paper
• CD4+ T Cells Are Dispensable for Induction of Broad Heterologous HIV Neutralizing Antibodies in Rhesus Macaques

  2021cites this paper
• AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest period.

  2021cites this paper
• Efficient Estimation under Data Fusion.

  2021cites this paper
• CTLA-4 Blockade, during HIV Virus-Like Particles Immunization, Alters HIV-Specific B-Cell Responses

  2020cites this paper
• Generating Survival Times Using Cox Proportional Hazards Models with Cyclic and Piecewise Time-Varying Covariates

  2020cites this paper
• COVID-19 Vaccines: “Warp Speed” Needs Mind Melds, Not Warped Minds

  2020cites this paper
• Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials

  2020cites this paper
• The immunologic dominance of an epitope within a rationally designed poly-epitope vaccine is influenced by multiple factors.

  2020cites this paper
• Myeloid Cell-Mediated Trained Innate Immunity in Mucosal AIDS Vaccine Development

  2020cites this paper
• A Systematic Approach to HIV-1 Vaccine Immunogen Selection

  2020cites this paper
• Prophylactic HIV vaccine: vaccine regimens in clinical trials and potential challenges

  2020cites this paper
• Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans

  2020cites this paper
• Production of Recombinant HIV-1 p24-Nef Protein in Two Forms as Potential Candidate Vaccines in Three Vehicles.

  2020cites this paper
• Vaccines for STIs: Present and Future Directions

  2020cites this paper
• Sexually Transmitted Infections: Advances in Understanding and Management

  2020influential citation
• A retrospective analysis of incident pregnancy in phase 1 and 2a HIV-1 vaccine study participants does not support concern for adverse pregnancy or birth outcomes

  2020cites this paper
• COVID-19 as milestone for the use of new vaccine types

  2020cites this paper
• Frequent and Durable Anti-HIV Envelope VIV2 IgG Responses Induced by HIV-1 DNA Priming and HIV-MVA Boosting in Healthy Tanzanian Volunteers

  2020cites this paper
• TLR-9 agonist and CD40-targeting vaccination induces HIV-1 envelope-specific B cells with a diversified immunoglobulin repertoire in humanized mice

  2020cites this paper
• Frequent Anti-V1V2 Responses Induced by HIV-DNA Followed by HIV-MVA with or without CN54rgp140/GLA-AF in Healthy African Volunteers

  2020cites this paper
• Rectal Acquisition of Simian Immunodeficiency Virus (SIV) SIVmac239 Infection despite Vaccine-Induced Immune Responses against the Entire SIV Proteome

  2020cites this paper
• Use of adenovirus type-5 vectored vaccines: a cautionary tale

  2020cites this paper
• Off the beaten path: Novel mRNA-nanoformulations for therapeutic vaccination against HIV.

  2020cites this paper
• ROLE OF VACCINES IN PREVENTION OF DISEASES: A REVIEW ILO

  2020cites this paper
• A Systemic Prime–Intrarectal Pull Strategy Raises Rectum-Resident CD8+ T Cells for Effective Protection in a Murine Model of LM-OVA Infection

  2020influential citation
• Review of preventative HIV vaccine clinical trials in South Africa

  2020cites this paper